AWA
NBIX icon

Arkadios Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Arkadios Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-156
Closed -$14K – 1328
2021
Q3 		$14K Sell
156
-59
-27% -$5.57K ﹤0.01% 1348
2021
Q2 		$20K Sell
215
-22
-9% -$2.11K ﹤0.01% 1293
2021
Q1 		$23K Buy
237
+128
+117% +$13.4K ﹤0.01% 937
2020
Q4 		$10K Buy
+109
New +$10.5K ﹤0.01% 961

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arkadios Wealth Advisors's NBIX Position: Q4 2021 in Review

Arkadios Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 156 shares — an estimated $14K sold.

Arkadios Wealth Advisors first reported a position in NBIX in Q4 2020 and held it in 4 quarters. The position peaked at $23K in Q1 2021. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

  • Arkadios Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 156 Neurocrine Biosciences shares in Q4 2021, an estimated $14K.
  • Arkadios Wealth Advisors first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 4 quarters.
  • Arkadios Wealth Advisors's Neurocrine Biosciences position peaked at $23K in Q1 2021.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on Arkadios Wealth Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.